EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.

Animals Antibodies, Monoclonal / pharmacology Apoptosis Biomarkers, Tumor / genetics Breast Neoplasms / drug therapy Cell Proliferation Epithelial-Mesenchymal Transition Female Gene Expression Regulation, Neoplastic Humans Membrane Glycoproteins / genetics Mice Mice, Inbred BALB C Mice, Nude Neoplasm Metastasis Neoplastic Stem Cells / drug effects Tumor Cells, Cultured Tumor Microenvironment / immunology Xenograft Model Antitumor Assays

Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
08 2020
Historique:
received: 03 09 2019
revised: 24 02 2020
accepted: 19 05 2020
pubmed: 27 5 2020
medline: 3 6 2021
entrez: 27 5 2020
Statut: ppublish

Résumé

Little is known about the role of epithelial membrane protein-2 (EMP2) in breast cancer development or progression. In this study, we tested the hypothesis that EMP2 may regulate the formation or self-renewal of breast cancer stem cells (BCSC) in the tumor microenvironment.

Identifiants

DOI: 10.1158/1535-7163.MCT-19-0850 PMID: 32451329 PMC: PMC7415657
pubmed: 32451329
pii: 1535-7163.MCT-19-0850
doi: 10.1158/1535-7163.MCT-19-0850
pmc: PMC7415657
mid: NIHMS1597945
doi:

Substances chimiques

Antibodies, Monoclonal 0
Biomarkers, Tumor 0
EMP2 protein, human 0
Membrane Glycoproteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1682-1695

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR000124
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA163971
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA143930
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA143931
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197585
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI028697
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
Eur J Histochem. 2018 Sep 03;62(3):
pubmed: 30362671
Stem Cell Reports. 2013 Dec 27;2(1):78-91
pubmed: 24511467
Cancer Res. 2008 Sep 15;68(18):7493-501
pubmed: 18794137
Stem Cells Int. 2018 Feb 28;2018:5416923
pubmed: 29681949
Biochim Biophys Acta. 2016 Mar;1863(3):382-391
pubmed: 26079100
J Biomed Sci. 2018 Mar 6;25(1):20
pubmed: 29506506
Breast Cancer Res Treat. 2016 Apr;156(2):261-9
pubmed: 26975188
Semin Cancer Biol. 2018 Dec;53:156-167
pubmed: 30471331
Cancer Res. 2007 Mar 1;67(5):2226-38
pubmed: 17332353
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
EMBO J. 2017 Feb 1;36(3):252-259
pubmed: 28007895
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38
pubmed: 25453096
Cell Stem Cell. 2015 Sep 3;17(3):260-71
pubmed: 26340526
Nat Med. 2011 Oct 23;17(11):1514-20
pubmed: 22019887
Clin Transl Oncol. 2019 Apr;21(4):433-442
pubmed: 30218306
Mol Cancer Ther. 2014 Apr;13(4):902-15
pubmed: 24448822
BMC Cancer. 2010 Dec 03;10:666
pubmed: 21129172
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Semin Cancer Biol. 2012 Jun;22(3):234-49
pubmed: 22484561
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Cancer Res. 2010 Jun 15;70(12):5163-73
pubmed: 20516116
J Intern Med. 2013 Aug;274(2):113-26
pubmed: 23844915
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Sci Rep. 2017 Oct 23;7(1):13856
pubmed: 29062075
Cancer Res. 2009 Feb 15;69(4):1302-13
pubmed: 19190339
J Vis Exp. 2015 Mar 22;(97):
pubmed: 25867607
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Int J Cancer. 2006 Apr 1;118(7):1699-712
pubmed: 16217747
Biomed Res Int. 2015;2015:158682
pubmed: 26504780
Cell Metab. 2018 Jul 03;28(1):69-86.e6
pubmed: 29972798
Oncogene. 2017 Oct 19;36(42):5793-5807
pubmed: 28604744
Clin Cancer Res. 2010 Jan 1;16(1):45-55
pubmed: 20028757
Exp Mol Pathol. 2016 Feb;100(1):145-50
pubmed: 26687806
Oncogene. 2013 Nov 14;32(46):5369-76
pubmed: 23334331
Oncotarget. 2016 Mar 8;7(10):11018-32
pubmed: 26783961
Sci Rep. 2016 Jun 13;6:27301
pubmed: 27292795
Clin Exp Metastasis. 2016 Jan;33(1):97-113
pubmed: 26445849

Auteurs

Christen Dillard (C)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Meagan Kiyohara (M)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Vei Mah (V)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Sean P McDermott (SP)

Department of Internal Medicine-Hematology/Oncology, University of Michigan, Ann Arbor, MI.

Dana Bazzoun (D)

Department of Internal Medicine-Hematology/Oncology, University of Michigan, Ann Arbor, MI.

Jessica Tsui (J)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Ann M Chan (AM)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Department of Internal Medicine-Hematology/Oncology, University of Michigan, Ann Arbor, MI.

Ghassan Haddad (G)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
ORCID: 0000-0002-0708-3545

Matteo Pellegrini (M)

Department of Molecular, Cell & Developmental Biology, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Yu-Ling Chang (YL)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
ORCID: 0000-0002-0789-4989

Yahya Elshimali (Y)

Center to Eliminate Cancer Health Disparities, Charles Drew University, Los Angeles, CA.

Yanyuan Wu (Y)

Center to Eliminate Cancer Health Disparities, Charles Drew University, Los Angeles, CA.

Jaydutt V Vadgama (JV)

Center to Eliminate Cancer Health Disparities, Charles Drew University, Los Angeles, CA.

Sara R Kim (SR)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Lee Goodglick (L)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Samuel M Law (SM)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Deven D Patel (DD)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
ORCID: 0000-0003-4417-5913

Puneet Dhawan (P)

Department of Surgery, Harbor UCLA, Torrance, CA.

Neil A O'Brien (NA)

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Lynn K Gordon (LK)

Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Jonathan Braun (J)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Gary Lazar (G)

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Max S Wicha (MS)

Department of Internal Medicine-Hematology/Oncology, University of Michigan, Ann Arbor, MI.

Madhuri Wadehra (M)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA. mwadehra@mednet.ucla.edu.
Center to Eliminate Cancer Health Disparities, Charles Drew University, Los Angeles, CA.
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transdifférenciation cellulaire › Transition épithélio-mésenchymateuse › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris nude › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches tumorales › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › EMP2 Is a Novel Regulator of Stemness in...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › EMP2 Is a Novel Regulator of Stemness in...